It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The emerging arena of space exploration has created opportunities to study cancer cell biology in the environments of microgravity and hypergravity. Studying cellular behavior in altered gravity conditions has allowed researchers to make observations of cell function that would otherwise remain unnoticed. The patient-derived QNS108 brain tumor initiating cell line (BTIC), isolated from glioblastoma (GBM) tissue, was launched on a suborbital, parabolic rocket flight conducted by EXOS Aerospace Systems & Technologies. All biologicals and appropriate ground controls were secured post-launch and transported back to our research facility. Cells from the rocket-flight and ground-based controls were isolated from the culture containers and expanded on adherent flasks for two weeks. In vitro migration, proliferation, and stemness assays were performed. Following cell expansion, male nude mice were intracranially injected with either ground-control (GC) or rocket-flight (RF) exposed cells to assess tumorigenic capacity (n = 5 per group). Patient-derived QNS108 BTICs exposed to RF displayed more aggressive tumor growth than the GC cells in vitro and in vivo. RF cells showed significantly higher migration (p < 0.0000) and stemness profiles (p < 0.01) when compared to GC cells. Further, RF cells, when implanted in vivo in the brain of rodents had larger tumor-associated cystic growth areas (p = 0.00029) and decreased survival (p = 0.0172) as compared to those animals that had GC cells implanted.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Mayo Clinic, Department of Neurosurgery, Jacksonville, USA (GRID:grid.417467.7) (ISNI:0000 0004 0443 9942); Stanford University School of Medicine, Palo Alto, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
2 Mayo Clinic, Department of Neurosurgery, Jacksonville, USA (GRID:grid.417467.7) (ISNI:0000 0004 0443 9942)
3 University of Kansas Medical Center, Department of Neurological Surgery, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375)
4 Mayo Clinic, Department of Critical Care Medicine, Jacksonville, USA (GRID:grid.417467.7) (ISNI:0000 0004 0443 9942)
5 Center for Applied Space Technology, Cape Canaveral, USA (GRID:grid.420467.3) (ISNI:0000 0000 9425 3244)
6 EXOS Aerospace Systems and Technologies, Greenville, USA (GRID:grid.420467.3)